top of page

UthPeak™: Agenda for Safety & Efficacy Validation

UthPeak is the only market-ready NMNH (Reduced NMN) with a clearly defined safety and efficacy validation agenda. We have conducted multiple toxicology tests across various matrices to ensure consumer safety and trust.

Pre-Clinical Studies

Jun.14, 2023

No mutagenicity

Bacterial reverse mutation test (Ames test)

Jun.15, 2023

No acute oral toxicity

Acute oral toxicity in rat

Jul. 25, 2023

Non-cytotoxic & Non-clastogenic

In vivo Chromosomal Aberration

test in Mouse

Aug. 31, 2023

Non-cytotoxic & Non-clastogenic

Bone Marrow In Vitro Mammalian

Cell Micronucleus test  in CHO K1 cel1 line

Nov. 30, 2023

No toxcitiy, NOALE ≥ 1000mg/kg BW

Repeated dose 90 days oral

toxicity study in rats

UthPeak™ Clinical Trial Timeline

The forthcoming UthPeak clinical trials will concentrate on assessing NMNH’s potential in enhancing consumer-centric well-being factors such as cardioprotection, energy enhancement, and liver protection.

2023

Toxicology Testing Completed

2024

Phase I - Clinical Trial

2025

Phase II - Clinical Trial

Subscribe to Learn the Lastest Progress of UthPeak™ Study

Thanks for submitting!

CONTACT

CONTACT US

EffePharm Ltd.

Thanks for submitting!

bottom of page